瑟瑞妥单抗
瑟瑞妥单抗（INN：Seribantumab[1]；开发代号：MM-121）是一种单克隆抗体，设计用于治疗癌症。[2]它与HER3的胞外结构域结合，阻断NRG1结合，从而阻止受体的激活。[3]
| 单克隆抗体 | |
|---|---|
| 种类 | ? |
| 目標 | HER3 |
| 臨床資料 | |
| 其他名稱 | MM-121 |
| ATC碼 |
|
| 识别信息 | |
| CAS号 | 1334296-12-6 |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化学信息 | |
| 化学式 | C6340H9810N1690O1986S52 |
| 摩尔质量 | 143,151.18 g·mol−1 |
参考资料
- ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 108 (PDF). WHO Drug Information. 2012, 26 (4) [2024-03-01]. （原始内容存档 (PDF)于2016-05-18）.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Seribantumab, American Medical Association.
- ^ Rendell A, Thomas-Bland I, McCuish L, Taylor C, Binju M, Yu Y. Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now?. Biomedicines. August 2022, 10 (9): 2113. PMC 9495728
. PMID 36140214. doi:10.3390/biomedicines10092113 .
